ERBB2 and breast carcinoma: Between 20% to 30% of breast cancers over-express the human epidermal growth factor receptor 2 (HER2)/avian erythroblastosis oncogene B2 (ERBB2) protein on their cell surface [2], and over-expression of HER2 is strongly linked to worse clinical prognosis [3].